awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q52623144-3C6F568D-3829-46A4-8A87-6DBBB659A28B
Q52623144-3C6F568D-3829-46A4-8A87-6DBBB659A28B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52623144-3C6F568D-3829-46A4-8A87-6DBBB659A28B
PARP inhibitors for homologous recombination-deficient prostate cancer.
P2860
Q52623144-3C6F568D-3829-46A4-8A87-6DBBB659A28B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52623144-3C6F568D-3829-46A4-8A87-6DBBB659A28B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e745ea747a742ad97c6f63eb7daf0df7e60ea36c
P2860
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.